DE69214587T2 - Methanoanthracene als Dopaminantagonisten - Google Patents

Methanoanthracene als Dopaminantagonisten

Info

Publication number
DE69214587T2
DE69214587T2 DE69214587T DE69214587T DE69214587T2 DE 69214587 T2 DE69214587 T2 DE 69214587T2 DE 69214587 T DE69214587 T DE 69214587T DE 69214587 T DE69214587 T DE 69214587T DE 69214587 T2 DE69214587 T2 DE 69214587T2
Authority
DE
Germany
Prior art keywords
formula
dihydro
methanoanthracen
chloro
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69214587T
Other languages
German (de)
English (en)
Other versions
DE69214587D1 (de
Inventor
Joseph James Lewis
Cyrus John Ohnmacht
Diane Amy Trainor
Ying Kwong Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117640A external-priority patent/GB9117640D0/en
Priority claimed from GB929207966A external-priority patent/GB9207966D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE69214587D1 publication Critical patent/DE69214587D1/de
Application granted granted Critical
Publication of DE69214587T2 publication Critical patent/DE69214587T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69214587T 1991-08-15 1992-08-11 Methanoanthracene als Dopaminantagonisten Expired - Lifetime DE69214587T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919117640A GB9117640D0 (en) 1991-08-15 1991-08-15 Compounds
GB929207966A GB9207966D0 (en) 1992-04-10 1992-04-10 Compounds

Publications (2)

Publication Number Publication Date
DE69214587D1 DE69214587D1 (de) 1996-11-21
DE69214587T2 true DE69214587T2 (de) 1997-03-20

Family

ID=26299412

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69214587T Expired - Lifetime DE69214587T2 (de) 1991-08-15 1992-08-11 Methanoanthracene als Dopaminantagonisten

Country Status (16)

Country Link
US (2) US5266570A (enExample)
EP (1) EP0532178B1 (enExample)
JP (1) JP3269574B2 (enExample)
KR (1) KR100238562B1 (enExample)
AT (1) ATE144254T1 (enExample)
AU (1) AU645707B2 (enExample)
CA (1) CA2076146A1 (enExample)
CZ (1) CZ251692A3 (enExample)
DE (1) DE69214587T2 (enExample)
FI (1) FI923664A7 (enExample)
GB (1) GB9216298D0 (enExample)
HU (1) HUT66515A (enExample)
IE (1) IE922589A1 (enExample)
IL (1) IL102808A0 (enExample)
NO (1) NO923200L (enExample)
TW (1) TW222265B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
US5514683A (en) * 1992-02-20 1996-05-07 James Black Foundation Limited Bicyclo 2,2,2!octane derivatives
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
BRPI0807125A2 (pt) * 2007-01-29 2014-04-08 Arete Therapeutics Inc Processo para a preparação de compostos de uréia substituídos por piperidinil
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CA2683111A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
MX2011000043A (es) 2008-07-03 2011-02-22 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas sustituidas como antagonistas del receptor 5-ht6.
DK2307374T3 (en) 2008-07-31 2017-05-01 Janssen Pharmaceutica Nv PIPERAZIN-1-YLTRIFLUORMETHYL-SUBSTITUTED PYRIDINES AS QUICK DISSOCATING DOPAMIN-2 RECEPTOR ANTAGONISTS
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74455C (enExample) *
BE610863A (fr) * 1960-11-29 1962-05-28 Ciba Geigy Procédé de préparation de nouvelles amines, entre autres de 9-amino-alcoyl-9,10-dihydro-9,10-éthano-(1,2)-anthracènes
US3632653A (en) * 1960-11-29 1972-01-04 Ciba Geigy Corp Ethano-anthracenes
BE674185A (enExample) * 1961-10-10
FR176F (enExample) * 1965-05-19
US3489799A (en) * 1967-09-26 1970-01-13 Ciba Geigy Corp Ethano-anthracenes
ES367292A1 (es) * 1968-05-16 1971-05-01 Ciba Geigy Procedimiento para la obtencion de 9-(aminoalquilo)-9,10- dihidro - 9,10-etanoantracenos sustituidos.
US3706765A (en) * 1969-01-03 1972-12-19 Ciba Geigy Corp Hydroxyethano-anthracenes
CH533079A (de) * 1969-03-25 1973-01-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen N-substituierten 9-(Aminoalkyl)-12-acyloxy-9,10-dihydro-9,10-äthanoanthrazenen
DE2021668A1 (de) * 1969-05-10 1970-11-19 Ciba Geigy Neue Amine und Verfahren zu ihrer Herstellung
US3795676A (en) * 1970-10-01 1974-03-05 Sandoz Ag 7-substituted pleiadenes and 8-substituted dibenzoheptalenes
US3870796A (en) * 1970-11-27 1975-03-11 Ciba Geigy Corp Pharmaceutical preparation
US4045580A (en) * 1971-02-23 1977-08-30 Ciba-Geigy Corporation Pharmaceutical preparation using 9-(2-hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes as antidepressants
US4017542A (en) * 1971-02-23 1977-04-12 Ciba-Geigy Corporation 9-(2-Hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes and salts thereof
JPS5911576B2 (ja) * 1975-07-07 1984-03-16 住友化学工業株式会社 新規なメタノ−アントラセン誘導体の製造法
GB1508669A (en) * 1974-12-13 1978-04-26 Sumitomo Chemical Co Methanoanthracene derivative and a process for the preparation thereof
US4358620A (en) * 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
JPS527972A (en) * 1975-07-07 1977-01-21 Sumitomo Chem Co Ltd Process for preparing novel morpholine derivatives
JPS5268170A (en) * 1975-12-03 1977-06-06 Sumitomo Chem Co Ltd Preparation of novel methano-anthracene derivatives
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
JPS5910654B2 (ja) * 1976-04-07 1984-03-10 住友化学工業株式会社 新規なメタノ−アントラセン誘導体
JPS597709B2 (ja) * 1976-07-05 1984-02-20 住友化学工業株式会社 新規なモルホリン誘導体及びその製造法
US4318926A (en) * 1979-08-14 1982-03-09 Ciba-Geigy Corporation Method of curing or alleviating herpes infections and pharmaceutical compositions suitable therefor
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
GB9117639D0 (en) 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JP3005176U (ja) 1994-05-30 1994-12-13 勝治 都竹 介護用シャツ

Also Published As

Publication number Publication date
FI923664L (fi) 1993-02-16
JPH05239026A (ja) 1993-09-17
NO923200D0 (no) 1992-08-14
NO923200L (no) 1993-02-16
CA2076146A1 (en) 1993-02-16
ATE144254T1 (de) 1996-11-15
HU9202642D0 (en) 1992-10-28
KR100238562B1 (ko) 2000-03-02
KR930004263A (ko) 1993-03-22
IL102808A0 (en) 1993-01-31
TW222265B (enExample) 1994-04-11
US5266570A (en) 1993-11-30
EP0532178B1 (en) 1996-10-16
CZ251692A3 (en) 1993-02-17
AU645707B2 (en) 1994-01-20
IE922589A1 (en) 1993-02-24
US5455246A (en) 1995-10-03
DE69214587D1 (de) 1996-11-21
GB9216298D0 (en) 1992-09-16
HUT66515A (en) 1994-12-28
FI923664A0 (fi) 1992-08-14
JP3269574B2 (ja) 2002-03-25
EP0532178A1 (en) 1993-03-17
AU2101592A (en) 1993-02-18
FI923664A7 (fi) 1993-02-16

Similar Documents

Publication Publication Date Title
DE69214587T2 (de) Methanoanthracene als Dopaminantagonisten
DE69330853T2 (de) Verfahren zur Herstellung von Aryl-piperazinyl-heterocyclischen Derivaten
DE69420579T2 (de) 9-HYDROXY-PYRIDO [1,2-a] PYRIMIDIN-4-ON-ETHER-DERIVATE
DE69431069T2 (de) Cyclische amidderivate als neurokinin a antagonisten
DE69033393T2 (de) Tertiäre alkyl funktionalisierte Piperazin-Derivate
DE60120138T2 (de) Amid-verbindungen und deren verwendung
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
DE69523155T2 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
DE69214588T2 (de) Methanoanthracene als Dopaminantagonisten
DE19851421A1 (de) Neue Pyrimidine, deren Herstellung und Verwendung
DE4219158A1 (de) Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69811930T2 (de) Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel
DE69733427T2 (de) Tetrahydrobezindol derivate
EP0221376B1 (de) N-substituierte Diphenylpiperidine
DE69414855T2 (de) N-(piperidinyl-1-alkyl)-substituierte cyclohexancarbonsäureamide als 5ht1a rezeptor antagonisten
DE69811556T2 (de) Chinoline und Chinazoline Verbindungen und ihre therapeutische Anwendung
DE68910451T2 (de) 1,4-benzoxazin- und 1,4-benzothiazin-derivate und verfahren zu deren herstellung.
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
DE69011054T2 (de) Substituierte cyclohexene mit zentraler Nervensystem-Wirkung.
DE69228307T2 (de) Imidazo(1,2-c)chinazolinderivate als antihypertensive und antidysurie
KR940003756B1 (ko) 환상 아미드 또는 이미드의 디아지닐피페리딘 유도체의 제조방법
EP0508370B1 (de) Kondensierte Diazepinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung
DE69227207T2 (de) 1-Piperazinyl-2-butene und 2-butyne, Zwischenverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19602505A1 (de) 1-(Pyrazol-4-Indol-3-yl)-Piperidine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

R071 Expiry of right

Ref document number: 532178

Country of ref document: EP